HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer
Abstract
To the Editor: Trastuzumab, an antibody against the protein product of the human epidermal growth factor receptor type 2 (HER2) gene, improves progression-free survival and overall survival when added to chemotherapy in patients with metastatic breast cancer.1 Initial trials enrolled patients with tumors that had a staining intensity of 2+ or 3+ for HER2 on immunohistochemical analysis, but in subsequent studies, the benefit was limited to tumors with HER2 amplification as determined by fluorescence in situ hybridization (FISH). Trastuzumab also improves disease-free survival and overall survival in the adjuvant setting.2 On the basis of its mechanism of action, . . .
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the NSABP B-31 adjuvant trastuzumab trial, 9.7% of patients that did not meet criteria for HER2 overexpression by FISH or IHC also benefitted from adjuvant trastuzumab.
“Consistent with this speculation are the results of the NSABP B-31 adjuvant trastuzumab trial, in which 9.7% of patients that did not meet criteria for HER2 overexpression by FISH or IHC also benefitted from adjuvant trastuzumab (Paik et al., 2008).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Paik et al., 2008
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · see citing works
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,355 · see citing works
Self-citationWolff, A. C., Hammond, M. E., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Côté, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A. S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434 · see citing works
Self-citationPaik, S., Bryant, J., Tan-Chiu, E., Romond, E. H., Hiller, W., Park, K., Brown, A., Yothers, G., Anderson, S., Smith, R. P., et al. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.11.852 · Cited by 484 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048 · see citing works
The Identification and Characterization of Breast Cancer CTCs Competent for Brain Metastasis
Zhang, L., Ridgway, L. D., Wetzel, M. D., Ngo, J., Yin, W., Kumar, D., Goodman, J. C., Groves, M. D., & Marchetti, D. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005109 · Cited by 521 · see citing works
Mason, N. J., Gnanandarajah, J. S., Engiles, J. B., Gray, F., Laughlin, D., Gaurnier-Hausser, A., Wallecha, A., Huebner, M., & Paterson, Y. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0088 · Cited by 178 · see citing works
- Authors
- Paik, S., Kim, C., & Wolmark, N.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-03-27
- Volume
- 358
- Issue
- 13
- Pages
- 1409-1411
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2080661875
- Cited by
- 426
- References
- 4
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 11 · 2023: 15 · 2022: 14 · 2021: 14 · 2020: 18 · 2019: 18 · 2018: 20 · 2017: 19 · 2016: 28 · 2015: 40 · 2014: 37 · 2013: 52 · 2012: 29
- FWCI
- 18.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Gastric Cancer Management and Outcomes
- Keywords
- HER2 status, trastuzumab, adjuvant therapy, breast cancer, HER2 amplification, fluorescence in situ hybridization, immunohistochemistry, disease-free survival, overall survival
- MeSH terms
- Trastuzumab, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Female, Gene Amplification, Humans, RNA, Messenger, Chemotherapy, Adjuvant, Erb-b2 Receptor Tyrosine Kinases, Genes, erbB-2, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
